Daio-Orengedokudo works as a cell-proliferating compound in endothelial cells.

Daio-Orengedokuto is a combination drug that has inhibitory effects on HMG-CoA reductase and pancreatic lipase. Here we investigated whether Daio-Orengedokuto has effects on vascular endothelial cells. To determine its effects on blood vessels, we examined roles of Daio-Orengedokuto in cell migration, cell apoptosis and cell cycle progression over bovine aortic endothelial cells (BAECs). Interestingly, Daio-Orengedokuto was shown to work as an anti-apoptotic agent, a cell cycle progressive agent and a cell-migration inducing agent in BAECs, whereas it was known to act as a tumor suppressor in cancer cells (unpublished data). The inducing effect of Daio-Orengedokuto on cell-cycle progression and cell migration in endothelium suggests that Daio-Orengedokuto may be referred to as a drug, inducing angiogenesis, healing wounds, and (or) remodeling vascular tissue. Then we further investigated which signaling molecules were activated by Daio-Orengedokuto and found that extracellular signal-regulated kinase (ERK) phosphorylation and IkappaB degradation were stimulated by the Daio-Orengedokuto treatment in BAECs. More interestingly, pretreatment with PD compound, an ERK inhibitor, blocked the anti-apoptosis induced by Daio-Orengedokuto. In conclusion, Daio-Orengedokuto plays a role in endothelial cell proliferation via activation of MAP kinase.